Based on 15-gene NGS panel testing, Liu et al. found that EGFR mutations were more common in PD-L1 negative expression group (TPS < 1%), ALK mutations were more common in PD-L1 intermediate group (TPS 1%–49%), and BRAF and MET mutations were more common in PD-L1 high group ( TPS ≥ 50%) in Chinese lung cancer patients [30]. This evidence concerns the gene EGFR and lung carcinoma.